Evotec and Celgene expand IPSC collaboration to include additional cell lines

$ 6 M payment to access additional cell lines

Topics: Corporate, Celgene, IPSC, Evotec Read More

Evotec and Celgene enter into strategic oncology partnership

Leveraging Evotec's phenotypic screening capabilities and compound libraries with an initial focus on solid tumours Upfront payment of $ 65 M, significant milestone payments and tiered royalties per programme

Topics: Corporate, Oncology, Celgene Read More